Clinical Trial Update: Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 trial update of pembrolizumab for T-cell lymphoma and NK-cell lymphoma is in progress with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nk-cell Lymphoma
• T-cell Lymphoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: The University of Hong Kong | Conditions: T-Cell Lymphoma, NK-Cell Lymphoma | Phase 2 | Status: UNKNOWN